TG Therapeutics Inc (TGTX) concluded trading on Thursady at a closing price of $13.44, with 3.68 million shares of worth about $49.46 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 27.39% during that period and on Thursady the price saw a gain of about 3.23%. Currently the company’s common shares owned by public are about 146.39M shares, out of which, 136.40M shares are available for trading.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 10 times over the past 12 months. They bought 1,250,000 shares in 7 of the transactions. In 3 selling transactions, insiders dumped 128,501 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stock saw a price change of -5.29% in past 5 days and over the past one month there was a price change of -14.99%. Year-to-date (YTD), TGTX shares are showing a performance of -21.31% which decreased to -17.39% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $6.46 but also hit the highest price of $35.67 during that period. The average intraday trading volume for TG Therapeutics Inc shares is 5.03 million. The stock is currently trading -10.89% below its 20-day simple moving average (SMA20), while that difference is down -17.64% for SMA50 and it goes to -17.32% lower than SMA200.
TG Therapeutics Inc (NASDAQ: TGTX) currently have 146.39M outstanding shares and institutions hold larger chunk of about 59.95% of that.
The stock has a current market capitalization of $2.03B and its 3Y-monthly beta is at 2.32. It has posted earnings per share of -$0.27 in the same period. It has Quick Ratio of 4.95 while making debt-to-equity ratio of 0.67. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TGTX, volatility over the week remained 4.16% while standing at 4.90% over the month.
Analysts are in expectations that TG Therapeutics Inc (TGTX) stock would likely to be making an EPS of -$0.1 in the current quarter, while forecast for next quarter EPS is -$0.1 and it is -$0.13 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.17 which is -$0.04 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.39 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 99.12% while it is estimated to decrease by -892.05% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Goldman on August 02, 2023 offering a Neutral rating for the stock and assigned a target price range of between $16 and $12 to it. Coverage by Jefferies stated TG Therapeutics Inc (TGTX) stock as a Buy in their note to investors on June 26, 2023, suggesting a price target of $40 for the stock. On May 20, 2022, BofA Securities Initiated their recommendations, while on February 23, 2022, B. Riley Securities Reiterated their ratings for the stock with a price target of $35. Stock get a Sell rating from Goldman on November 15, 2021.
